Sunday, November 15, 2026

Peer-Reviewed Clinical Evidence Platform

The research that matters, without the jargon.

Peer-reviewed breakthroughs in plain English alongside verified outcomes, evidence grades, and clinical study details for everyone from everyday readers to medical students.

ClearMed Editorial Digest500 briefings across 12 specialties121 Phase III & clinical practice

Indexed from PubMed, NEJM, The Lancet, JAMA, Nature MedicineSaved Library

Health Hubs:

Stage: Evidence:

Showing 36 briefings matching “diabetes”

Reset all filters

Filtered Archive

Matching Peer-Reviewed Briefings

Peer-Reviewed Clinical Digests · Verified Scientific Media

AI in Medicine editorial photograph for ClinicalAge, a framework for modelling ageing trajectories from longitudinal electronic health records in the UK: a model development and validation study

AI IN MEDICINE · CLINICAL PRACTICE

ClinicalAge, a framework for modelling ageing trajectories from longitudinal electronic health records in the UK: a model development and validation study

Your Medical Records Could Reveal Your True 'Biological Age' — And Predict Your Health Future. A new AI tool, ClinicalAge, uses your existing health records to calculate your biological age, offering a powerful predictor of future health risks and lifespan.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readThe Lancet Digital HealthNov 15, 2026

NEUROLOGY · PHASE III

Broccoli Compound Shows Promise Against Friedreich Ataxia by Boosting Frataxin and Neuroprotection

A natural compound from broccoli significantly boosts frataxin levels and activates neuroprotective pathways in preclinical models of Friedreich ataxia, offering a promising, affordable disease-modifying therapy. Currently, there are no approved disease-modifying therapies for Friedreich ataxia, and patient management is predominantly symptomatic and supportive, encompassing physical therapy, cardiac interventions, and diabetes management.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readScienceDailyNov 12, 2026

CARDIOLOGY · REAL-WORLD COHORT

Daily Avocado & Mango: New Heart Health Allies?

Daily intake of avocado and mango may positively impact blood vessel health and diastolic blood pressure, offering a simple dietary intervention for cardiovascular well-being. This research suggests a simple, nutrient-rich dietary adjustment could offer a straightforward way to support cardiovascular health, especially for at-risk populations like those with prediabetes.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDailyNov 12, 2026

GASTROENTEROLOGY · REAL-WORLD COHORT

Prevalence of liver fibrosis and steatotic liver disease in community-dwelling adults in China (the CHESS-LiverHealth project): cross-sectional baseline data from a prospective cohort study

Silent Liver Damage: A Hidden Epidemic in China's Adult Population. Liver scarring and fatty liver disease are widespread among Chinese adults, largely fueled by metabolic issues and alcohol.

4/5 Strong Trial

Evidence Meter · 4/5

Strong Clinical Evidence

Tested directly in patients through a prospective clinical trial or large multicenter human cohort.

1 min readThe Lancet Gastroenterology & HepatologyNov 15, 2026

ENDOCRINOLOGY · CLINICAL PRACTICE

Ozempic in Pregnancy: Diabetes, Not Drug, Linked to Early Births?

The reason you're taking Ozempic or Wegovy matters during pregnancy, with underlying diabetes potentially posing a greater risk than the medication itself. This study challenges the previously held, often generalized, assumption that GLP-1 medications alone are responsible for pregnancy complications.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDailyNov 13, 2026

CARDIOLOGY · PHASE III

Coronary Artery Calcium Scoring Challenges Traditional Statin Prescription Guidelines

Coronary Artery Calcium (CAC) guided statin initiation resulted in similar major cardiovascular event rates with fewer prescriptions and significantly improved patient adherence compared to traditional risk assessments. Current standard of care for primary prevention statin initiation heavily relies on calculated risk scores (e.g., ASCVD risk in the US), which estimate the 10-year risk of atherosclerotic cardiovascular disease events based on factors like age, sex, race, cholesterol levels, blood pressure, and diabetes status.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readScienceDailyNov 12, 2026

CARDIOLOGY · PHASE III

Coronary Artery Calcium Scoring: A New Paradigm for Statin Allocation and Adherence?

Using coronary artery calcium (CAC) scoring to guide statin initiation reduces statin prescriptions without compromising major cardiovascular event prevention, while significantly improving medication adherence. Current guidelines from bodies like the ACC/AHA primarily utilize traditional risk assessment tools, such as the Pooled Cohort Equations, to identify individuals at intermediate to high risk for atherosclerotic cardiovascular disease (ASCVD) who would benefit from statin therapy.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readScienceDailyNov 12, 2026

PHARMACOLOGY · PRECLINICAL

Electric Implant: Novel Glucose Control and Weight Loss for Type 2 Diabetes

An electronic implant effectively lowered blood sugar and promoted weight loss in diabetic mice by converting excess glucose for urinary excretion. This breakthrough offers a potential new paradigm for type 2 diabetes management, particularly for patients who struggle with current insulin or drug regimens.

2/5 Preclinical

Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readScienceDailyNov 12, 2026

PHARMACOLOGY · REAL-WORLD COHORT

Intensive Lifestyle Reverses Type 2 Diabetes in Younger Adults

Lifestyle intervention combining diet and exercise can induce type 2 diabetes remission in over half of younger adults, presenting a powerful alternative to lifelong medication. This breakthrough highlights a potent non-pharmacological pathway to potentially reverse type 2 diabetes, especially in younger populations.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDailyNov 12, 2026

CARDIOLOGY · RANDOMIZED CLINICAL TRIAL

First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial

Oral semaglutide reduced the risk of first plus subsequent 3-P MACE vs placebo (inactive comparison treatment), highlighting the benefit of oral semaglutide in reducing the total burden of clinical morbidity and risk of death in this high-risk population. This was a prespecified secondary analysis of the double-blind, placebo-controlled, event-driven, phase 3b SOUL randomized clinical trial, conducted from June 2019 to September 2024 with a median (IQR) follow-up of 49.5 (44.0-54.9) months at 444 centers in 33 countries.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readJAMA CardiologyNov 11, 2026

GASTROENTEROLOGY · PHASE III

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study

In patients with MASH, 48 weeks of pemvidutide treatment led to significant reductions in non-invasive tests of MASH inflammation and fibrosis (tissue scarring), suggesting continued improvement in liver health. These data warrant the continued investigation of pemvidutide in a Phase 3 trial.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Gastroenterology & HepatologyNov 11, 2026

ENDOCRINOLOGY · REAL-WORLD COHORT

Clinical Guidance for Disease-Modifying Immunotherapy in Children and Adolescents With New-Onset (Stage 3) Type 1 Diabetes

Teplizumab-specific recommendations are identified, with broader principles framed for adaptation across health systems. This article addresses who should lead care, how to approach eligibility and timing, how to assess β-cell reserve and infection risk, how to sequence treatment with diabetic ketoacidosis recovery and early education, and how to monitor treatment safely.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readDiabetes CareNov 11, 2026

Showing 12 of 36 medical briefings

Interactive Fact Check